Impact of the UKPDS - An overview

Diabetic Medicine

Volumn 25, Issue SUPPL. 2, 2008, Pages 2-8

  Home, P D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Clinical guidelines; Diabetes care; UK Prospective Diabetes Study

Indexed keywords

ATENOLOL; CAPTOPRIL; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL EDUCATION; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT FAILURE;

BLOOD GLUCOSE; DIABETES MELLITUS; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; PROSPECTIVE STUDIES;

EID: 47649102586     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02501.x     Document Type: Review

References (36)

1. Buxton M, Hanney S. How can payback from health services research be assessed? J Health Serv Res Policy 1996 1 : 35 43.
2. Hanney SR, Home PD, Frame I, Grant J, Green P, Buxton MJ. Identifying the impact of diabetes research. Diabet Med 2006 23 : 176 184.
3. Diabetes Trials Unit. UK Prospective Diabetes Study Publications. Available at http://www.dtu.ox.ac.uk/index.php?maindoc/ukpds/ Last accessed 31 March 2008.
4. UKPDS Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with Type 2 diabetes. Br Med J 1998 317 : 720 726.
5. UKPDS Group. Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with Type 2 diabetes. Br Med J 2000 320 : 1373 1378.
6. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for Type 2 diabetes. J Am Med Assoc 2002 287 : 2542 2551.
7. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati F et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 : S27 S40.
8. European Diabetes Policy Group 1999. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999 16 : 716 730.
9. The National Collaborating Centre for Chronic Conditions. Type 2 Diabetes (Update). London: Royal College of Physicians, 2008. Available at http://www.rcplondon.ac.uk/pubs/Specialty.aspx Last accessed 31 March 2008.
10. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield : ScHARR, University of Sheffield, 2001. Available at http://www.nice.org.uk Last accessed 31 March 2008.
11. DF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels : International Diabetes Federation, 2005. Available at http://www.idf.org Last accessed 31 March 2008.
12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003 27 : S1 S152.
13. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet 1998 352 : 837 853.
14. Council for the advancement of diabetes research and education (CADRE). Core slide kit. Available at http://www.cadre-diabetes.org/r_core_slide_kit.asp Last accessed 31 March 2008.
15. Worldwide Initiative for Diabetes Education. Slide resources. Available at http://www.worldwidediabetes.org/system/html_site/slide_resources/ slide_resources.htm Last accessed 31 March 2008.
16. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes. Lancet 1998 352 : 854 865.
17. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000 321 : 405 412.
18. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus Type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003 17 : 314 322.
19. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
20. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
21. Home P. Safety of very tight blood glucose control in Type 2 diabetes. Br Med J 2008 336 : 458 459.
22. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 : 829 40.
23. Holman RR, Turner RC. The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocrinol (Oxf) 1981 14 : 279 286.
24. The Diabetes Control Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
25. 1c - a marker for complications of Type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003 41 : 1182 1190.
26. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR et al. UK Prospective Diabetes Study (UKPDS 23). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. Br Med J 1998 316 : 823 828.
27. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991 34 : 877 890.
28. Nattrass M, Todd PG, Hinks L, Lloyd B, Alberti KGMM. Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics. Diabetologia 1977 13 : 145 152.
29. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 : 1711 1721.
30. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
31. GlaxoSmithKline. Advisory committee briefing document cardiovascular safety of rosiglitazone, FDA Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. King of Prussia: GlaxoSmithKline, 2007. Available at http://www.fda.gov/ohrms/dockets/ ac/07/briefing/2007-4308b1-01-sponsor-backgrounder.pdf Last accessed 31 March 2008.
32. Al-Ozairi E, Sibal L, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas? Diabetes Care 2007 30 : 1677 1680.
33. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. Br Med J 1998 317 : 703 713.
34. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000 321 : 412 419.
35. UK Prospective Diabetes Study Group. UKPDS 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes 1995 44 : 1249 1258.
36. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008 358 : 580 591.